Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3999 - Population sizes of patients (pts) with node negative (N0), HR+, HER2− primary breast cancer (BC), using standard and TAILORx 21-gene Recurrence Score (RS) cut-off values (COV)

Date

11 Sep 2017

Session

Poster display session

Presenters

Jens-Uwe Blohmer

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

J. Blohmer1, M. Verrill2, C. Fortmann3, C. Chao3, J. Gligorov4

Author affiliations

  • 1 Klinik Für Gynäkologie Mit Brustzentrum, Charité-Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 2 Northern Institute For Cancer Research, Newcastle University, Newcastle upon Tyne/GB
  • 3 Medical Affairs, Genomic Health, Inc., Redwood City/US
  • 4 Department Of Medical Oncology, APHP, Hôpital Tenon, Paris/FR
More

Resources

Abstract 3999

Background

Whether to use adjuvant chemotherapy (CT) is a crucial decision for pts with HR+, HER2− primary BC. The 21-gene Recurrence Score® (RS) assay is validated to predict adjuvant CT benefit and risk of recurrence, using standard RS COV of 

Methods

Pts with N0, HR+, HER− primary BC and RS results from 2004 to April 2017 were included (data from Genomic Health). Subgroup sizes were determined for RS 

Results

Of 609,247 unique RS records analyzed, 513,035 were from the US, 29,248 from EU countries, and 66,964 from RoW. The relative population sizes of RS subgroups were highly consistent across geographical regions. Deviations in percentages for each RS range were within ±3% (Table). Across all regions, >50% of pts had RS 

Conclusions

Our analysis revealed highly consistent RS subgroup classifications across geographic regions, mirroring observations from registry studies, suggesting that tumor biology as characterized by RS results does not vary by geography. Our findings therefore support the generalizability of outcomes-study results using standard or custom COV across geographic regions.

Clinical trial identification

N/A

Legal entity responsible for the study

Jens-Uwe Blohmer

Funding

Genomic Health

Disclosure

M. Verrill: Speaker/advisory/research support: Amgen, Genomic Health, Novartis/GSK, Roche. Speaker/advisor: AstraZeneca, Eisai, Teva. Advisor/research support: Pfizer. Advisor: Merck. C. Fortmann, C. Chao: Employment and stock ownership: Genomic Health. J. Gligorov: Advisor: Eisai, Genomic Health, Novartis, Pfizer, Roche. Research support; Eisai, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.